Press Releases July 21, 2026 06:45 AM

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026

BioNTech Announces Upcoming Q2 2026 Financial Results and Corporate Update on August 4, 2026

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
BNTX

BioNTech SE, a leading biopharmaceutical company specializing in innovative cancer treatments, will release its financial results for the second quarter of 2026 on August 4, 2026. The company will also host a live conference call to discuss these results and provide a corporate update.

BioNTech to Report Second Quarter 2026 Financial Results and Corporate Update on August 4, 2026
BNTX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • BioNTech will announce Q2 2026 financial results on August 4, 2026, followed by a conference call and webcast.
  • The company focuses on developing next-generation cancer therapeutics including immunotherapies and antibody drug conjugates.
  • BioNTech collaborates with several global pharmaceutical partners such as Pfizer, Bristol Myers Squibb, and Genentech to accelerate innovation in oncology treatments.

MAINZ, Germany, July 21, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the second quarter 2026 on Tuesday, August 4, 2026. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.

To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link.

Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at www.BioNTech.com. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.

About BioNTech

BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.

For more information, please visit www.BioNTech.com.

CONTACTS

Investor Relations
Douglas Maffei, PhD
[email protected]

Media Relations
Jasmina Alatovic
[email protected]


Risks

  • Financial results may not meet investor expectations, impacting stock performance.
  • Ongoing development and commercialization of oncology therapies involve clinical and regulatory uncertainties.
  • Dependence on partnerships and collaborations may pose risks if alliances underperform or dissolve.

More from Press Releases

Sachem Capital Reports Third Quarter 2026 Results Nov 16, 2026 Inter&Co Delivers Record 3Q26 Net Income of US$76.1 Million, With Strong Growth, Higher Margin and Better Efficiency Nov 12, 2026 Super League to Report Third Quarter 2026 Financial Results on Monday, November 16, 2026 Nov 12, 2026 UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026